THELMA Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 1,658.09 million compared to KRW 3,215.65 million a year ago. Net loss was KRW 983.3 million compared to KRW 1,369.77 million a year ago. Basic loss per share from continuing operations was KRW 40 compared to KRW 100 a year ago. Diluted loss per share from continuing operations was KRW 40. Basic loss per share was KRW 40 compared to KRW 100 a year ago.
For the nine months, sales was KRW 5,891.74 million compared to KRW 7,525.3 million a year ago. Net loss was KRW 3,734.41 million compared to KRW 8,317.39 million a year ago. Basic loss per share from continuing operations was KRW 152 compared to KRW 632 a year ago. Diluted loss per share from continuing operations was KRW 152. Basic loss per share was KRW 152 compared to KRW 632 a year ago.